Human Immunodeficiency Virus
Conditions
Brief summary
This trial will assess the potential impact of a vaginal ring on condom use by comparing the performance (total clinical failure, clinical slippage, and clinical breakage) of a standard male lubricated latex condom when the female partner is wearing the vaginal ring and when the female partner is not wearing the vaginal ring.
Interventions
COMBINATION_PRODUCTPlacebo Vaginal Ring
a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.
DEVICECondom
Male condom
Sponsors
International Partnership for Microbicides, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Intervention model description
IPM 029 is an open-label, randomized, two-period, crossover non-inferiority trial conducted at two research centers in the U.S. to assess condom functionality during vaginal intercourse in healthy, monogamous heterosexual, sexually active couples.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Mutually monogamous heterosexual couples; current relationship ≥3 months; and who can give written informed consent; 2. Age ≥18 to ≤45 years (females) or ≥18 to ≤55 years (males) at time of the screening visit; 3. Healthy on the basis of medical history; 4. Not at risk of pregnancy, i.e., female is surgically sterile, using an IUD, or using effective hormonal contraception, or has a vasectomized partner. The use of vaginal contraceptive rings will not be allowed; 5. Sexually active and agree to have at least 8 acts of penile-vaginal intercourse using a study condom over 2 periods of up to 4 weeks each; 6. Agree to use only the condoms provided by trial personnel during the time of participation. Additional lubricant will be provided; use of non-study lubricants will not be allowed; 7. Agree to not use other vaginal products, except menstrual absorption products (e.g. tampons) and study lubricant during the trial; 8. Available for all visits and consent to follow all procedures scheduled for the trial; 9. At low risk for HIV infection.
Exclusion criteria
1. Males with untreated erectile dysfunction; 2. Female with positive pregnancy test; 3. Either partner allergic to natural latex or vaginal lubricants such as Astroglide ®; 4. History by self-report of recurrent or a recently-treated (within past 2 weeks) sexually transmitted infection (e.g. gonorrhea, syphilis, chlamydia) or HIV(+); 5. Currently using condoms for protection against sexually transmitted infection; 6. Either partner taking any topical or oral medication to treat a urogenital condition at enrollment, except medication for the male partner to treat erectile dysfunction (e.g., tadalafil, sildenafil); 7. Either partner with a self-reported or clinically diagnosed urogenital condition (e.g. itching, burning, irritation, etc.) that, in the opinion of the Investigator, could affect use of the study condoms or ability to interpret trial data; 8. Females, based on findings from a pelvic examination, who are not suitable candidates for wearing the vaginal ring (anatomical condition, current vaginal infection, etc.); 9. Current participation in a study or other research involving a drug, device or other product; 10. Any condition(s) that, in the opinion of the Investigator, might interfere with adherence to trial requirements or evaluation of the trial objectives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total clinical failure rate (N slipped or broken/N total) off the penis or broke during intercourse or withdrawal, divided by the number of condoms used during intercourse. | 4 weeks |
Countries
United States
Outcome results
None listed